Download PDF
Thromb Haemost 1991; 66(04): 474-478
DOI: 10.1055/s-0038-1646441
Review Article
Schattauer GmbH Stuttgart

PAI-1 Plays an Important Role in the Expression of t-PA Activity in the Euglobulin Clot Lysis by Controlling the Concentration of Free t-PA

Tetsumei Urano
The Department of Physiology, Hamamatsu University, School of Medicine, Hamamatsu-shi, Japan
,
Kenichi Sumiyoshi
*   The Department of Surgery, Hamamatsu University, School of Medicine, Hamamatsu-shi, Japan
,
Michal H Pietraszek
The Department of Physiology, Hamamatsu University, School of Medicine, Hamamatsu-shi, Japan
,
Yumiko Takada
The Department of Physiology, Hamamatsu University, School of Medicine, Hamamatsu-shi, Japan
,
Akikazu Takada
The Department of Physiology, Hamamatsu University, School of Medicine, Hamamatsu-shi, Japan
› Author Affiliations
Further Information

Publication History

Received 18 June 1990

Accepted 09 April 1991

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The antigen levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) were assayed in the plasma and in the euglobulin fraction, and their contributions to the euglobulin clot lysis time (ECLT) and t-PA activity were analyzed. Total and free PAI-1 levels in both fractions showed significant positive correlation with ECLT (p <0.001), whereas t-PA antigen level did not have a high correlation coefficient with ECLT. t-PA activity showed significant negative correlation with ECLT (p <0.001) and positive correlation with free t-PA level (p <0.001), which was calculated by the ratio of the concentrations of t-PA-PAI-1 complex and the free PAI-1. Thus free t-PA seems to dissolve the euglobulin clot and its concentration seems to be controlled by the concentration of free PAI-1. These findings were confirmed by the analyses of the effects of C1-inactivator and antibody against t-PA to regular ECLT and kaolin activated ECLT, the latter of which was only inhibited by the addition of C1-inactivator whereas the former was inhibited by anti-t-PA antibody.

 

  • References

  • 1 Marsh M. Measurement of fibrinolysis and fibrinolytic components. In: Fibrinolysis.. John Wiley & Sons, New York: 1981. pp 206-41
    Google Scholar
  • 2 Davidson JF, Walker ID. Assessment of the fibrinolytic system. In: Haemostasis and Thrombosis.. Bloom AL, Thomas DP. (eds) Churchill Livingstone, New York: 1987. pp 953-66
    Google Scholar
  • 3 Brommer EJP, Schicht I, Wijingaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemostas 1984; 52: 311-4
    PubMedGoogle Scholar
  • 4 Rijken DC, Juhan-Vague I, de Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-84
    PubMedGoogle Scholar
  • 5 Rijken DC, Wijingaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-20
    CrossrefPubMedGoogle Scholar
  • 6 Cole E, Bachmann F, Marchant L. Plasminogen activators from porcine tissues: enzymatic and immunological properties. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol.3.. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) Raven Press, New York: 1978. pp 99-106
    Google Scholar
  • 7 Kluft C. Levels of plasminogen activators in human plasma: new methods to study the intrinsic and extrinsic activators. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol. 3.. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) Raven Press, New York: 1978. pp 141-54
    Google Scholar
  • 8 Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemostas 1990; 63: 82-6
    PubMedGoogle Scholar
  • 9 Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (RAM). Thromb Haemostas 1988; 59: 329-32
    PubMedGoogle Scholar
  • 10 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-4
    PubMedGoogle Scholar
  • 11 Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988; 262: 199-210
    CrossrefPubMedGoogle Scholar
  • 12 Kruithof EKO, Chien TT, Bachmann F. The fast acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-9
    PubMedGoogle Scholar
  • 13 Chmielewska J, Rånby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Evidence for "second-site" interactions. Biochem J 1988; 251: 327-32
    CrossrefPubMedGoogle Scholar
  • 14 Kato K, Fukui H, Hamaguchi Y, Ishikawa E. Enyzme-linked immunoassay: conjugation of the Fab' fragment of rabbit IgG with β-D-galactosidase from E. coli and its use for immunoassay. J Immunol 1976; 116: 1554-60
    PubMedGoogle Scholar
  • 15 Takada A, Takada Y. Interaction of C1s and C1 inactivator in the presence of heparin, dextran sulfate and protamine sulfate. Thromb Res 1980; 18: 847-59
    CrossrefPubMedGoogle Scholar
  • 16 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Coolen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5
    PubMedGoogle Scholar
  • 17 Rydzewski A, Takada Y, Takada A. Determination of plasminogen activator inhibitor-1 (PAI-1) in plasma using two different anticoagulants and methods. Thromb Res 1989; 55: 285-9
    CrossrefPubMedGoogle Scholar
  • 18 Carlson RH, Garnick RL, Jones AJS, Meunier AM. The determination of recombinant human tissue type plasminogen activator by turbidimetry using a microcentrifugal analyzer. Anal Biochem 1988; 168: 428-35
    CrossrefPubMedGoogle Scholar
  • 19 Urano S, Metzger AR, Castellino FJ. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators. Proc Natl Acad Sci USA 1989; 86: 2568-71
    CrossrefPubMedGoogle Scholar
  • 20 Takada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 1986; 42: 63-72
    CrossrefPubMedGoogle Scholar
  • 21 Takada Y, Takada A. Measurement of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma. Thromb Res 1988; Suppl VIII 15-22
    PubMedGoogle Scholar
  • 22 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-83
    PubMedGoogle Scholar
  • 23 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Haemostasis and Thrombosis.. Coller BS. (ed) W B. Saunders Company, Philadelphia, PA: 1989. pp 87-115
    Google Scholar
  • 24 Granelli-Piperno A, Reich M. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34
    CrossrefPubMedGoogle Scholar
  • 25 Kruithof EKO, Tran-Thang C, Ransjin A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-14
    PubMedGoogle Scholar
  • 26 Wun TC, Capuano A. Inhibition and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987; 69: 1354-62
    PubMedGoogle Scholar
  • 27 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-5
    PubMedGoogle Scholar